Lynparza® (olaparib) tablets receive approval as maintenance therapy treatment for ovarian cancer regardless of BRCA status

Tuesday, May 8, 2018 Cancer News
Email Print This Page Comment bookmark
Font : A-A+

______________________________________i AstraZeneca Canada Inc., Lynparza® (olaparib) tablet Product Monograph. May 2018

ii Ibid.

iii Ibid.

iv Ibid.

v Ibid.

vi Ibid.

vii Ovarian Cancer Canada. About Ovarian Cancer. Accessed April 11, 2018. Available at: http://www.ovariancanada.org/about-ovarian-cancer

viii Ovarian Cancer Canada. About Ovarian Cancer. Disease Basics. Accessed April 18, 2018. Available at: http://ovariancanada.org/About-Ovarian-Cancer/Disease-Basics/What-is-ovarian-cancer 

ix AstraZeneca Canada Inc., Health Canada approves Lynparza™ for the Treatment of Ovarian Cancer in Patients with BRCA-Mutations. Newswire.ca. May 2016. Accessed April 11, 2018. https://www.newswire.ca/news-releases/health-canada-approves-lynparza-for-the-treatment-of-ovarian-cancer-in-patients-with-brca-mutations-577929961.html

x Ovarian Cancer Canada. About Ovarian Cancer. Accessed April 11, 2018. Available at: http://www.ovariancanada.org/about-ovarian-cancer

xi Ovarian cancer: Survival statistics. Accessed April 11, 2018 Available at: http://www.statcan.gc.ca/pub/82-624-x/2015001/article/14212-eng.htm#a1

xii Ovarian Cancer Canada. Hereditary One-Pager. Page 2. On file.

Advertisement


Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store